No Data
Sailong Pharmaceutical Group (002898.SZ): Received the approval notice for the listing application of the Chemical Raw Materials Active Pharmaceutical Ingredient famotidine.
On January 1st, Gelonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the "Approval Notice for the Marketing Application of Chemical Raw Materials for Famotidine" issued by the National Medical Products Administration. Famotidine formulation is mainly used to treat upper gastrointestinal bleeding caused by digestive ulcers, as well as mucosal erosion and bleeding of the stomach and duodenum due to various causes other than tumors and esophageal or gastric varices.
Sailong Pharmaceutical Group (002898.SZ): Participating in the tenth batch of national Pharmaceutical centralized procurement, expected to win the bid.
On December 13, Glonghui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical (Changsha) Co., Ltd. (hereinafter referred to as "Changsha Sailong") participated in the bidding work organized by the Joint Procurement Office (hereinafter referred to as "Joint Procurement Office") for the tenth batch of national centralized procurement of pharmaceuticals. Some of the company's products are expected to win bids in this centralized procurement.
Sailong Pharmaceutical Group (002898.SZ) has obtained the supplementary approval letter for Pregabalin Capsules.
Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., recently received...
Sailong Pharmaceutical Group (002898.SZ): Sailong Polaris has cumulatively reduced its shareholding by 1%.
On November 4th, Geronghui reported that Sailong Pharmaceutical Group (002898.SZ) recently received a notification letter from shareholder Zhuhai Hengqin New Area Sailong Juzhi Investment Co., Ltd., holding more than 5% of the shares, about the change in equity reaching 1%. It was learned that following the company's previous disclosure of the announcement of shareholders reducing their holdings by more than 1%, Sailong Juzhi reduced the company's shares by 130,000 shares through centralized auction trading from November 26, 2022, to November 28, 2022, between May 4, 2023, and June 2, 2023, through centralized auction trading.
Cailong Pharmaceuticals: Report for the third quarter of 2024
Sailong Pharmaceutical Gets Approval Notice for Fluorouracil Listing
Some Confidence Is Lacking In Sailong Pharmaceutical Group Co.,Ltd. (SZSE:002898) As Shares Slide 29%